Deciphera Pharmaceuticals
Deciphera Pharmaceuticals, a leading biopharmaceutical company headquartered in the United States, focuses on developing innovative therapies for cancer and other serious diseases. Founded in 2003, the company has made significant strides in the oncology sector, particularly with its proprietary drug discovery platform that targets specific molecular pathways. With a strong presence in the US and expanding operations globally, Deciphera is renowned for its core product, ripretinib, which offers a unique approach to treating gastrointestinal stromal tumours (GIST). The company’s commitment to advancing precision medicine has positioned it as a notable player in the industry, achieving key milestones such as successful clinical trials and regulatory approvals. Deciphera Pharmaceuticals continues to drive innovation, aiming to improve patient outcomes through its cutting-edge therapies.
DitchCarbon Score
How does Deciphera Pharmaceuticals's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Deciphera Pharmaceuticals's score of 68 is higher than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Deciphera Pharmaceuticals, headquartered in the US, currently does not have specific carbon emissions data available for reporting. As a current subsidiary of Ono Pharmaceutical Co., Ltd., any climate commitments or emissions data may be influenced by the parent company's initiatives. Deciphera Pharmaceuticals has not publicly disclosed any reduction targets or specific climate pledges. However, it is important to note that emissions data and climate strategies may be cascaded from Ono Pharmaceutical Co., Ltd., which is actively engaged in sustainability efforts. As the company continues to develop its environmental strategies, stakeholders can look forward to potential future commitments aligned with industry standards.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | - | 0,000,000 | - | - | - | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | 00,000,000 | - | - | - | 00,000,000 | 00,000,000 | 0,000,000 |
| Scope 3 | - | - | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Deciphera Pharmaceuticals is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
